American Renal Associates Holdings (American Renal Associates Holdings) 3-Year EBITDA Growth Rate : 0.00% (As of Sep. 2020)

View and export this data going back to 2016. Start your Free Trial

What is American Renal Associates Holdings 3-Year EBITDA Growth Rate?

American Renal Associates Holdings's EBITDA per Share for the three months ended in Sep. 2020 was $0.94.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison of American Renal Associates Holdings's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, American Renal Associates Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

American Renal Associates Holdings's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Renal Associates Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where American Renal Associates Holdings's 3-Year EBITDA Growth Rate falls into.

American Renal Associates Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

American Renal Associates Holdings (NYSE:ARA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

American Renal Associates Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of American Renal Associates Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

American Renal Associates Holdings (American Renal Associates Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Renal Associates Holdings Inc (NYSE:ARA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 6550, Beverly, MA, USA, 01915

Website

https://www.americanrenal.com

American Renal Associates Holdings Inc is a joint venture-focused dialysis services provider in the United States. The company through its subsidiary is engaged in providing kidney dialysis services for patients suffering from chronic kidney failure, also known as end-stage renal disease. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure.

Executives

Don E Williamson	officer: EVP, Chief Operating Officer	500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Victoria Labriola	officer: VP and General Counsel	AMERICAN RENAL HOLDINGS, INC. 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Joseph A Carlucci	director, officer: Chief Executive Officer	C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Syed T Kamal	director, officer: President	C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Jeremy Gelber	director	C/O CENTERBRIDGE PARTNERS, L.P., 375 PARK AVE, 12TH FLOOR, NEW YORK NY 10152
Christopher J Hocevar	director	1601 CHESTNUT STREET SHAREHOLDER SERVICES TL05Y PHILADELPHIA PA 19192
Robert H Fish	director	C/O SKILLED HEALTHCARE 27442 PORTOLA PARKWAY, SUITE 200 FOOTHILL RANCH CA 92610
Michael Boxer	director	9151 BOULEVARD 26 NORTH RICHLAND HILLS TX 76180
John M Jureller	director	FRONTIER COMMUNICATIONS, 401 MERRITT 7, NORWALK CT 06851
Thomas W Erickson	director	OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Jason Boucher	officer: Former VP & CFO	500 CUMMINGS CENTER SUITE 6550 BEVERLY MA 01915
Mark Herbers	officer: Interim CFO and Interim CAO	500 CUMMINGS CENTER, SUITE 6550, BEVERLY MA 01915
Michael Ray Costa	officer: VP and General Counsel	C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Patrick T Ryan	director	401 EDGEWATER PLACE, SUITE 500, WAKEFIELD MA 01880
Jonathan L Wilcox	officer: VP & Chief Financial Officer	C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915